These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 37089382)
1. Identification of novel prognostic model based on homologous recombination deficiency associated lncRNAs in lung adenocarcinoma. Liu X; Wang T; Ren Z; Feng C; Tian X Heliyon; 2023 Apr; 9(4):e14811. PubMed ID: 37089382 [TBL] [Abstract][Full Text] [Related]
2. A Risk Model Developed based on Homologous Recombination Deficiency Genes for Evaluating the Drug Sensitivity and Prognostic Prediction of Lung Adenocarcinoma. Hong L; Li J; Shao W Curr Med Chem; 2024 Oct; ():. PubMed ID: 39354765 [TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma. Chen JH; Wu X; Wang ZM; Liu ZY; He BX; Song WP; Zhang WZ J Thorac Dis; 2023 Mar; 15(3):1373-1386. PubMed ID: 37065578 [TBL] [Abstract][Full Text] [Related]
4. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma. Ma S; Zhu J; Wang M; Zhu J; Wang W; Xiong Y; Jiang R; Seetharamu N; AbrĂ£o FC; Puthamohan VM; Liu L; Jiang T Transl Lung Cancer Res; 2022 Oct; 11(10):2079-2093. PubMed ID: 36386454 [TBL] [Abstract][Full Text] [Related]
5. Prognostic model and immunotherapy prediction based on molecular chaperone-related lncRNAs in lung adenocarcinoma. Xu Y; Tao T; Li S; Tan S; Liu H; Zhu X Front Genet; 2022; 13():975905. PubMed ID: 36313456 [No Abstract] [Full Text] [Related]
6. Establishment of a prognostic signature for lung adenocarcinoma using cuproptosis-related lncRNAs. Yalimaimaiti S; Liang X; Zhao H; Dou H; Liu W; Yang Y; Ning L BMC Bioinformatics; 2023 Mar; 24(1):81. PubMed ID: 36879187 [TBL] [Abstract][Full Text] [Related]
7. Immunogenic cell death-related long noncoding RNA influences immunotherapy against lung adenocarcinoma. Sun D; Zhang C Oncol Res; 2023; 31(5):753-767. PubMed ID: 37547766 [TBL] [Abstract][Full Text] [Related]
8. Identification and Validation of a Novel Necroptosis-Related Long Noncoding RNA Prognostic Signature for Lung Adenocarcinoma. Zeng C; Yu H; Liu X; Liu Q; Jin J Biomed Res Int; 2022; 2022():9710540. PubMed ID: 36330457 [TBL] [Abstract][Full Text] [Related]
9. Molecular typing and prognostic model of lung adenocarcinoma based on cuprotosis-related lncRNAs. Zheng M; Zhou H; Xie J; Zhang H; Shen X; Zhu D J Thorac Dis; 2022 Dec; 14(12):4828-4845. PubMed ID: 36647499 [TBL] [Abstract][Full Text] [Related]
10. Identification and Validation of a Three Pyroptosis-Related lncRNA Signature for Prognosis Prediction in Lung Adenocarcinoma. Liu J; Liu Q; Shen H; Liu Y; Wang Y; Wang G; Du J Front Genet; 2022; 13():838624. PubMed ID: 35928454 [TBL] [Abstract][Full Text] [Related]
11. Cross-talk between necroptosis-related lncRNAs to construct a novel signature and predict the immune landscape of lung adenocarcinoma patients. Wu J; Song D; Zhao G; Chen S; Ren H; Zhang B Front Genet; 2022; 13():966896. PubMed ID: 36186456 [No Abstract] [Full Text] [Related]
12. Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma. Li Y; Shen R; Wang A; Zhao J; Zhou J; Zhang W; Zhang R; Zhu J; Liu Z; Huang JA Front Cell Dev Biol; 2021; 9():648806. PubMed ID: 33869203 [TBL] [Abstract][Full Text] [Related]
13. A Novel Necroptosis-Related lncRNA Signature Predicts the Prognosis of Lung Adenocarcinoma. Lu Y; Luo X; Wang Q; Chen J; Zhang X; Li Y; Chen Y; Li X; Han S Front Genet; 2022; 13():862741. PubMed ID: 35368663 [No Abstract] [Full Text] [Related]
14. Pan-cancer analysis identifies proteasome 26S subunit, ATPase (PSMC) family genes, and related signatures associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma. Jia H; Tang WJ; Sun L; Wan C; Zhou Y; Shen WZ Front Genet; 2022; 13():1017866. PubMed ID: 36699466 [No Abstract] [Full Text] [Related]
15. Identification of immunotherapy biomarkers for improving the clinical outcome of homologous recombination deficiency patients with lung adenocarcinoma. Zhou X; Xu R; Lu T; Xu R; Wang C; Peng B; Chang X; Shen Z; Wang K; Shi J; Zhao J; Zhang LY Aging (Albany NY); 2023 Aug; 15(16):8090-8112. PubMed ID: 37578930 [TBL] [Abstract][Full Text] [Related]
16. A novel tumor mutation-related long non-coding RNA signature for predicting overall survival and immunotherapy response in lung adenocarcinoma. Chen W; Liao C; Xiang X; Li H; Wu Q; Li W; Ma Q; Chen N; Chen B; Li G Heliyon; 2024 Apr; 10(7):e28670. PubMed ID: 38586420 [TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Genomic Instability of m Li R; Li JP; Liu TT; Huo C; Yao J; Ji XL; Qu YQ Front Cell Dev Biol; 2022; 10():707405. PubMed ID: 35309906 [No Abstract] [Full Text] [Related]
18. Identification of a apoptosis-related LncRNA signature to improve prognosis prediction and immunotherapy response in lung adenocarcinoma patients. Luo T; Yu S; Ouyang J; Zeng F; Gao L; Huang S; Wang X Front Genet; 2022; 13():946939. PubMed ID: 36171881 [TBL] [Abstract][Full Text] [Related]
19. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma. Wang F; Lin H; Su Q; Li C World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740 [TBL] [Abstract][Full Text] [Related]
20. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma. Zhao J; Lin X; Zhuang J; He F Front Genet; 2021; 12():714697. PubMed ID: 34777460 [No Abstract] [Full Text] [Related] [Next] [New Search]